

Affymetrix® DMET™ Plus Products

The following publications and review articles demonstrate the importance and the utility of Affymetrix DMET Plus Products in pharmacogenomic studies, clinical research, and the development of personalized medicine. The uses described in these reference articles have not been approved or cleared by FDA.

Technology reviews

Burmester J. K., *et al.* DMET microarray technology for pharmacogenomics-based personalized medicine. *Methods in Molecular Biology* 632:99-124 (2010).

Sissung T. M., *et al.* Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. *Pharmacogenomics* 11(1):89-103 (2010).

Deeken J. F. The Affymetrix DMET platform and pharmacogenetics in drug development. *Current Opinion in Molecular Therapeutics* 11(3):260-268 (2009).

Identification of new drug-related biomarkers

Caldwell M. D., *et al.* CYP4F2 genetic variant alters required warfarin dose. *Blood* 111(8):4106-12 (2008).*

McDonald M. G., *et al.* CYP4F2 Is a vitamin K1 hydroxylase: A molecular explanation for altered warfarin dose in carriers of the functionally defective V433M variant. *15th North American Regional ISSX meeting* Abstract 67 (2008).

Drug development and safety research

Mega J. L., *et al.* Cytochrome p-450 polymorphisms and response to clopidogrel. *New England Journal of Medicine* 360(4):354-62 (2009).

U.S. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix).

Dumaul C., *et al.* Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. *Pharmacogenomics* 8(3):293-305 (2007).

Daly T. M., *et al.* Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. *Clinical Chemistry* 53(7):1222-30 (2007).

Genotype/phenotype databasing

Man M., *et al.* Genetic variation in metabolizing enzyme and transporter genes: Comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. *Journal of Clinical Pharmacology* doi: 10.1177/0091270009355161 (2010).

UNC's McCleod discusses 'practical' approach to bringing pharmacogenetics to all countries. *GenomeWeb Pharmacogenomics Reporter* (2010).

Affymetrix, Inc. Coriell Institute for Medical Research selects Affymetrix DMET™ Plus Product for national personalized medicine project. Press release (2009).



Biomarkers in oncology

Deeken J. F., *et al.* A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. *The Pharmacogenomics Journal*, doi: 10.1038/tpj.2009.57 (2009).

Deeken J. F., *et al.* A pharmacogenetic study of docetaxel and thalidomide in patients with androgen-independent prostate cancer (AIPC) using targeted human DMET genotyping platform. *Journal of Clinical Oncology* 2007 ASCO Annual Meeting Proceedings Part I. 25(18S):3580 (2007).

*This study was supported by Affymetrix

Affymetrix, Inc. Tel: +1-888-362-2447 ■ Affymetrix UK Ltd. Tel: +44-(0)1628-552550 ■ Affymetrix Japan K.K. Tel: +81-(0)3-6430-4020
Panomics Products Tel: +1-877-PANOMICS www.panomics.com ■ USB Products Tel: +1-800-321-9322 www.usb.affymetrix.com

www.affymetrix.com Please visit our website for international distributor contact information.
For research use only. Not for use in diagnostic procedures.